CA2330644A1 - Solution containing nicotine - Google Patents

Solution containing nicotine Download PDF

Info

Publication number
CA2330644A1
CA2330644A1 CA002330644A CA2330644A CA2330644A1 CA 2330644 A1 CA2330644 A1 CA 2330644A1 CA 002330644 A CA002330644 A CA 002330644A CA 2330644 A CA2330644 A CA 2330644A CA 2330644 A1 CA2330644 A1 CA 2330644A1
Authority
CA
Canada
Prior art keywords
nicotine
solution
person
per
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002330644A
Other languages
English (en)
French (fr)
Inventor
Eric C. Westman
Jed E. Rose
Keith F. Tomlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2330644A1 publication Critical patent/CA2330644A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002330644A 1998-04-30 1999-04-21 Solution containing nicotine Abandoned CA2330644A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/070,263 US6211194B1 (en) 1998-04-30 1998-04-30 Solution containing nicotine
US09/070,263 1998-04-30
PCT/US1999/008752 WO1999055371A1 (en) 1998-04-30 1999-04-21 Solution containing nicotine

Publications (1)

Publication Number Publication Date
CA2330644A1 true CA2330644A1 (en) 1999-11-04

Family

ID=22094213

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002330644A Abandoned CA2330644A1 (en) 1998-04-30 1999-04-21 Solution containing nicotine

Country Status (7)

Country Link
US (1) US6211194B1 (enExample)
EP (1) EP1073466A4 (enExample)
JP (1) JP2002512978A (enExample)
AU (1) AU745292B2 (enExample)
CA (1) CA2330644A1 (enExample)
NZ (1) NZ507845A (enExample)
WO (1) WO1999055371A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268386B1 (en) * 1998-06-25 2001-07-31 Marshall Anlauf Thompson Nicotine beverage
US6358060B2 (en) * 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
US20020098264A1 (en) * 1998-11-27 2002-07-25 Cherukuri Subraman R. Medicated chewing gum delivery system for nicotine
JP2004512907A (ja) * 2000-11-03 2004-04-30 リカバリー　ファーマシューティカルズ　インコーポレーティッド 禁煙用の装置および方法
US20050131031A1 (en) * 2001-12-10 2005-06-16 Thompson Marshall A. Method of producing a nicotine composition
US20030108592A1 (en) * 2001-12-10 2003-06-12 Thompson Marshall Anlauf Method of producing a nicotine composition
US20060204598A1 (en) * 2001-12-10 2006-09-14 Thompson Marshall A Nicotine-alternative compositions and methods of producing such compositions
US20060105023A1 (en) * 2001-12-10 2006-05-18 Knight Joseph R Treatment of neurological disorders with nicotine
EP1461037B1 (en) * 2001-12-10 2007-08-01 Joseph Robert Knight Process for preparation of a beverage treated with a nicotine containing substance
US20100160376A1 (en) * 2001-12-10 2010-06-24 Marshall Anlauf Thompson Nicotine-alternative compositions and methods of producing such compositions
SE0104388D0 (sv) * 2001-12-27 2001-12-27 Pharmacia Ab New formulation and use and manufacture thereof
US7767698B2 (en) * 2002-06-03 2010-08-03 Mcneil Ab Formulation and use thereof
US20040002520A1 (en) * 2002-07-01 2004-01-01 Soderlund Patrick L. Composition and method for cessation of Nicotine cravings
DK1803443T3 (en) * 2002-12-20 2019-02-25 Niconovum Ab Nicotine-containing particulate material with a crystalline cellulose
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
CN104397869B (zh) 2003-11-07 2016-06-08 美国无烟烟草有限责任公司 烟草组合物
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US7766018B2 (en) 2004-09-30 2010-08-03 Smoke-Break, Inc. Device and composition for reducing the incidence of tobacco smoking
JP2008528028A (ja) * 2005-01-27 2008-07-31 マーシャル アンラーフ トンプソン ニコチン組成物の製造方法
US8642016B2 (en) * 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
AU2006348180A1 (en) * 2006-09-13 2008-03-20 Warner Chilcott Company, Llc Methods of treatment for ulcerative colitis
US20100048519A1 (en) * 2006-09-13 2010-02-25 Chyon-Hwa Yeh Methods of treatment for ulcerative colitis using aminosalicylate
ES2521494T3 (es) * 2007-04-02 2014-11-12 Parkinson's Institute Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
EP2706854A4 (en) * 2011-05-09 2014-12-03 Envivo Pharmaceuticals Inc TREATMENT OF COGNITIVE DISORDERS BY CERTAIN AGONISTS OF THE ALPHA-7 NICOTINIC RECEPTOR IN COMBINATION WITH NICOTINE
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
KR102705152B1 (ko) 2013-05-06 2024-09-09 쥴 랩스, 인크. 에어로졸 장치를 위한 니코틴 염 제제 및 그 방법
KR102957402B1 (ko) 2013-12-05 2026-04-24 쥴 랩스, 인크. 에어로졸 장치를 위한 니코틴 액제 및 그 방법
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
EP3267875A4 (en) 2015-03-12 2018-12-05 Chrono Therapeutics Inc. Craving input and support system
US20170165252A1 (en) 2015-12-10 2017-06-15 Niconovum Usa Inc. Protein-enriched therapeutic composition
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
US20210255202A1 (en) 2018-06-13 2021-08-19 Michael R. D'Andrea Methods and dosing regimens for preventing or delaying onset of alzheimer's disease and other forms of dementia and mild congnitive impairment
EP3807260B1 (en) 2018-06-15 2024-09-18 R. J. Reynolds Tobacco Company Purification of nicotine
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
BR102020002169A2 (pt) * 2020-01-31 2021-08-10 Bruno Ghizoni Da Silva Comércio De Produtos E Serviços Inovadores-Me Bebida estimulante

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR899037A (fr) 1942-06-17 1945-05-15 Metallguss & Presswerk H Diehl Alliage de zinc ductile
US3870794A (en) * 1974-02-20 1975-03-11 Foundation For Behavioral Rese Treatment of certain emotional disorders with nicotine compounds
GB2142822B (en) 1983-06-29 1987-02-11 Alec Stanley Walter Shaw Nicotine lozenges
GB8317576D0 (en) 1983-06-29 1983-08-03 Shaw A S W Consumer tobacco products
DE3639418A1 (de) 1986-11-18 1988-06-09 Forschungsgesellschaft Rauchen Nikotinhaltiges mittel
EP0395683A4 (en) * 1987-11-19 1991-01-30 Indaus International Pty Ltd Nicotine compositions
JP2695247B2 (ja) * 1988-06-13 1997-12-24 ビーエーエスエフ・ケー・アンド・エフ・コーポレイシヨン コレスチルアミンを含有する食用の焼いた組成物
US5026555A (en) * 1988-10-28 1991-06-25 Warner-Lambert Co. Method for preparing an anion exchange resin delivery system
SE8904295D0 (sv) 1989-12-21 1989-12-21 Pharmacia Ab Smoking substitute
US5147654A (en) * 1990-07-23 1992-09-15 Alza Corporation Oral osmotic device for delivering nicotine
US5135753A (en) * 1991-03-12 1992-08-04 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
US5596007A (en) * 1992-05-18 1997-01-21 Pharmaco Behavioral Associates, Inc. Therapeutic method to alleviate the craving associated with cessation of tobacco with cotinine
US5383478A (en) 1993-01-12 1995-01-24 Duke University Low tar and low nicotine cigarette adapted to provide enhanced smoking satisfaction
IT1266565B1 (it) 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5549906A (en) 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
JP3188073B2 (ja) * 1993-09-28 2001-07-16 武田薬品工業株式会社 飲用液組成物
CN1089834A (zh) * 1993-10-14 1994-07-27 王子芸 戒烟口胶的配方及加工工艺
US5810018A (en) * 1994-12-29 1998-09-22 Monte; Woodrow C. Method, composition and apparatus for reducing the incidence of cigarette smoking

Also Published As

Publication number Publication date
AU745292B2 (en) 2002-03-21
WO1999055371A1 (en) 1999-11-04
US6211194B1 (en) 2001-04-03
EP1073466A1 (en) 2001-02-07
EP1073466A4 (en) 2001-08-16
AU3754799A (en) 1999-11-16
NZ507845A (en) 2003-09-26
JP2002512978A (ja) 2002-05-08

Similar Documents

Publication Publication Date Title
AU745292B2 (en) Solution containing nicotine
RU2279871C2 (ru) Жидкая фармацевтическая композиция, содержащая никотин, для введения в полость рта
Rose Nicotine and nonnicotine factors in cigarette addiction
Henningfield et al. Drinking coffee and carbonated beverages blocks absorption of nicotine from nicotine polacrilex gum
DK2023958T3 (en) PHARMACEUTICAL PRODUCT FOR INTRAORAL DELIVERY OF NICOTINE COMPREHENSIVE TROMETAMOL AS BUFFER
US6845777B2 (en) Composition to reduce or quit smoking addiction
US20070163610A1 (en) Formulation and Use and Manufacture Thereof
US20080286341A1 (en) Buffered coated nicotine containing products
JP2002512978A5 (enExample)
HUT74920A (en) Improved nicotine lozenge and therapeutic method for smoking cessation
EP2152313A1 (en) Oral nicotine formulation buffered with amino acid
JP2004512907A (ja) 禁煙用の装置および方法
US20030008005A1 (en) Sublingual administration of dihydroergotamine for the treatment of migraine
US20100113453A1 (en) Sublingual Formulations of D-Cycloserine and Methods of Using Same
Prignot Pharmacological approach to smoking cessation
Ebert et al. Effect of nicotine chewing gum on plasma nicotine levels of cigarette smokers
US5130132A (en) Composition and method for treating nicotine dependency
MXPA00010494A (en) Solution containing nicotine
Chauhan et al. Nicotine replacement therapy for smoking cessation
Miller et al. Nicotine dependence: diagnosis, chemistry and pharmacological treatments
Wells Use of pharmacologic agents for smoking cessation
Patel et al. Use of pharmacologic agents for smoking cessation.
Roopchandani et al. Smoking cessation aids
Whittaker Nicotine replacement therapy: medicine cupboard
Rose et al. Nicotine replacement therapies and other nicotinic strategies

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued